TerminatedPhase 2NCT03449524
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Complexa, Inc.
- Principal Investigator
- Theo Danoff, MDComplexa, Inc.
- Intervention
- 75mg CXA-10(drug)
- Enrollment
- 69 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2018 – 2020
Study locations (30)
- University of Alabama, Birmingham, Alabama, United States
- Arizona Pulmonary Specialists, Phoenix, Arizona, United States
- University of Arizona, Tucson, Arizona, United States
- University of California San Francisco, San Francisco, California, United States
- University of Colorado Health, Aurora, Colorado, United States
- National Jewish Health, Denver, Colorado, United States
- Washington Hospital (Medstar), Washington D.C., District of Columbia, United States
- George Washington Medical Faculty Associates, Washington D.C., District of Columbia, United States
- University of Florida Health, Gainesville, Florida, United States
- Mayo Clinic, Jacksonville, Florida, United States
- University of Miami, Miami, Florida, United States
- AdventHealth, Orlando, Florida, United States
- University of Chicago, Chicago, Illinois, United States
- Loyola University, Maywood, Illinois, United States
- Indiana University, Indianapolis, Indiana, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Medpace, Inc. · Philips Healthcare · Cardiovascular Clinical Sciences Inc · MicroConstants · Innovative Analytics · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03449524 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07529821Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive PatientsFoundation University Islamabad
- ACTIVE NOT RECRUITINGNCT07312227A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaMassachusetts General Hospital
- ENROLLING BY INVITATIONNANCT07558460Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialIstanbul University - Cerrahpasa
- RECRUITINGPHASE2NCT07318597Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)Regeneron Pharmaceuticals
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →